ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC was delisted on the 16th of October, 2018.
16 hedge funds and large institutions have $684K invested in ImmunoCellular Therapeutics, Ltd. in 2016 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 17 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
48% less funds holding
Funds holding: 31 → 16 (-15)
52% less capital invested
Capital invested by funds: $1.43M → $684K (-$743K)
88% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$129K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$26.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$2.07K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
+$476 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$396 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
California Public Employees Retirement System
Sacramento,
California
|
-$25K |
| 2 |
Bank of New York Mellon
New York
|
-$10K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$10K |
| 4 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$9K |
| 5 |
Luther King Capital Management (LKCM)
Fort Worth,
Texas
|
-$7K |
IMUC Hedge Fund Activity: Q4 2016 in Review
16 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics, Ltd. (IMUC) for Q4 2016, worth a combined $684K — down 52% from $1.43M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of IMUC and 2 opened new positions — a net loss of 15 holders — while 4 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, adding an estimated $129K. The largest seller was California Public Employees Retirement System, exiting entirely with an estimated $25K sold.
- 16 institutional investors held ImmunoCellular Therapeutics, Ltd. (IMUC) as of Q4 2016, down from 31 in Q3 2016.
- Funds reported $684K of ImmunoCellular Therapeutics, Ltd. stock for Q4 2016, down 52% quarter-over-quarter.
- 2 funds opened new ImmunoCellular Therapeutics, Ltd. positions in Q4 2016 and 17 closed out, a net change of -15 holders.
- The largest ImmunoCellular Therapeutics, Ltd. buyer in Q4 2016 was Renaissance Technologies, an estimated $129K added.
- The largest ImmunoCellular Therapeutics, Ltd. seller in Q4 2016 was California Public Employees Retirement System, an estimated $25K sold.
Based on aggregated 13F filings for Q4 2016.